A Comparison of Tc 99m Tilmanocept Quantitative Imaging with Immunohistochemical (IHC) Analysis of CD206 Expression in Synovial Tissue from Subjects Clinically Diagnosed with Rheumatoid Arthritis (RA)

avidea Biopharmaceuticals Ltd0 个研究点目标入组 24 人开始时间: 2019年11月22日最近更新: 2020年10月6日

适应症

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方
入组人数: 24

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•1. The subject has provided written informed consent with HIPAA (Health Information Portability and Accountability Act) or equivalent authorization before the initiation of any study-related procedures.
•2. Women and men of childbearing potential must use adequate birth control measures (e.g., abstinence, oral contraceptives, intrauterine device, barrier method with spermicide, or surgical sterilization) for the duration of the study.
•3. The subject is at least 18 years of age and was = 18 years of age at the time of RA diagnosis.
•4. The subject has RA as determined by the 2010 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Classification Criteria (score of = 6/10 at or before screening).
•5. The subject has a 28-joint disease activity score (DAS28) of = 3.2 (includes the C-reactive protein [CRP] test and visual analog scale [VAS]).
•6. Subjects receiving traditional DMARDs must have been on therapy for = 90 days and at a stable dose for = 30 days prior to the first imaging visit (Day 0).
•7. If the subject is receiving biologic disease-modifying antirheumatic drug (bDMARD) or janus kinase (JAK) inhibitor therapy, they have been at a stable dose > 60 days prior to the imaging visit (Day 0). bDMARD therapy should not be administered less than 4 days prior to the imaging visit.
•8. If the subject is receiving NSAIDs (nonsteroidal anti-inflammatory drug) or oral corticosteroids, the dose has been at a stable dose for = 28 days prior to imaging. The corticosteroid dose should be = 10 mg/day of prednisone or an equivalent steroid dose.
•9. The subject has a hand or wrist joint with a minimum ultrasound gray-scale synovitis score of 2 (range 0 to 3).
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 16
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 8

排除标准

•1. The subject is pregnant or lactating.
•2. The subject size or weight is not compatible with imaging per the investigator.
•3. The subject has had or is currently receiving radiation therapy or chemotherapy.
•4. The subject has had a finger, hand, and/or wrist amputation or hand or wrist joint arthroplasty.
•5. The subject has renal insufficiency as demonstrated by a glomerular filtration rate of < 60 mL/min.
•6. The subject has hepatic insufficiency as demonstrated by ALT (alanine aminotransferase [SGPT]) or AST (aspartate aminotransferase [SGOT]) greater than 3 times the upper limit of normal.
•7. The subject has any severe, acute, or chronic medical conditions and/or psychiatric conditions and/or laboratory abnormalities that would impart, in the judgment of the investigator, excess risk associated with study participation or study drug administration that would deem the subject inappropriate for study participation.
•8. The subject has a known allergy to or has had an adverse reaction to dextran exposure.
•9. The subject has received an investigational product within 30 days prior to the Tc 99m tilmanocept administration (Day 0).
•10. The subject has received injectable (e.g., intra-articular, intramuscular, etc.) corticosteroids = 8 weeks prior to imaging (Day 0).
•11. The subject has received any radiopharmaceutical within 7 days or 10 half-lives prior to the administration of Tc 99m tilmanocept (Day 0).
•12. The subject has an intolerance to anesthetic and antiseptic agents indicated for the synovial biopsy procedure.
•13. The subject is currently receiving anticoagulants (oral anti-platelet agents are permitted) or has a condition that is contraindicated with ultrasound-guided synovial biopsy e.g., needle phobia.

研究者

发起方

avidea Biopharmaceuticals Ltd

相似试验

终止

2 期

Comparison of Tc 99m Tilmanocept Imaging With IHC Analysis of CD206 Expression in Synovial Tissue of Subjects With RARheumatoid Arthritis

NCT04078191Navidea Biopharmaceuticals20

终止

3 期

Tc 99m Tilmanocept Imaging for Early Prediction of Anti-TNFα Therapy Response in Moderate to Severe Active RARheumatoid Arthritis

NCT05246280Navidea Biopharmaceuticals169

已完成

不适用

Application of IV 99mTc-tilmanocept for Imaging of Macrophage-specific InflammationHIV

NCT03523130Massachusetts General Hospital9

进行中（未招募）

1 期

MET-PET-study - A comparative study of Tc-99m- sestamibi SPECT/ldCT and C-11-L-Methionin PET/diagnostic CT and their ability to locate paratyroid adenomas preoperatively.

EUCTR2013-004886-14-DKDep. Nuclear medicine, Odense university hospital60

尚未招募

3 期

Comparison of a 1.25 mg/ml intralesional triamcinolone acetonide with combination of a 1.25 mg/ml intralesional triamcinolone acetonide and comedone extraction in healing of inflammatory acnes in moderate-to-severe adult acne: a randomized, split-face controlled trialmoderate to severe acneInflammatory acne, intralesional triamcinolone acetatonide, intralesional corticosteroid

TCTR20210924008Dermatology unit, department of internal medicine, Chulalongkorn university40